Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands ...

A number of US pharmaceutical groups have recently made announcements about expanding domestic manufacturing. These include ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product ...

Biogen Inc. closed 47.73% short of its 52-week high of $238.00, which the company reached on July 12th.

Searching For Answers C-Suite Leaders Awards The San Francisco Business Times is now seeking nominations for our annual C-Suite Leaders Awards, which highlights leading local executives and their ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

Biogen appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

Biogen Inc. closed 48.82% short of its 52-week high of $238.00, which the company reached on July 12th.

Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher ...